Abstract Details

Title Medical Cannabis in the Treatment of Neuropathy

Topic Pain

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-012

Objective To evaluate the efficacy and adverse effects of medical cannabis (MC) in the treatment of neuropathy.

Background

According to the NIH, more than 20 million Americans suffer from neuropathy. With MC now legal in 33 states, MC presents as an anti-inflammatory and neuroprotective agent that may help in treating neuropathy and associated symptoms.

Design/Methods

This retrospective chart analysis was conducted on patients with neuropathy as diagnosed by a board-certified neurologist in a neurologic outpatient setting in Buffalo, NY. All patients were certified to use MC as part of New York State’s Medical Marijuana Program.

Results 152 (85=male, 67= female) patients age 22-95 years with neuropathy were included for this analysis. 78.9% of the study population reported benefit from using MC, with 76% percent of patient population (n=116) reporting a decrease in neuropathic pain. 44% (n=67) of the patient population were using an opioid upon initiation of MC treatment, subsequently 22% (n=15) were able to reduce their consumption of opioids. 70% of the study population used only one MC product with the most commonly administered via oral tincture (61%). 20:1 (THC:CBD) and 1:1 (THC:CBD) were the most commonly used ratios, representing more than 80% of MC products. Side effects were reported by 40% (n=61) of the population with the most common being fatigue (11%), increased appetite (4.61%), and euphoria (4.61%). Only 10 patients chose to stop treatment with MC due to side effects. No severe AEs were reported.

Conclusions MC in combination with other neuropathy treatments is largely well tolerated with 78.9% of the population reporting benefit and may have a role in a comprehensive neuropathic care plan. The most common MC ratios used to achieve such results were 20:1 (THC:CBD) and 1:1 (THC:CBD). Further investigations, such as a randomized placebo-controlled trials are needed to confirm these promising results in the treatment of neuropathy.

Authors/Disclosures
Laszlo Mechtler, MD, FEAN, FASN, FAHS, F�鶹��ýӳ�� (Dent Neurologic Institute) PRESENTER	Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel Pharma. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Mechtler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Hyperfine. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Mechtler has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Genomate Health. The institution of Dr. Mechtler has received research support from The Harry Dent Family Foundation, Inc. The institution of Dr. Mechtler has received research support from Alpheus medical. The institution of Dr. Mechtler has received research support from Shiratronics. The institution of Dr. Mechtler has received research support from Abbvie Inc. The institution of Dr. Mechtler has received research support from Amgen. The institution of Dr. Mechtler has received research support from Eli Lilly Company. The institution of Dr. Mechtler has received research support from H. Lundbeck HS. The institution of Dr. Mechtler has received research support from Pfizer. The institution of Dr. Mechtler has received research support from Hyperfine. Dr. Mechtler has received personal compensation in the range of $100,000-$499,999 for serving as a Ownership interest with Neurology Practce Consortium GPO. Dr. Mechtler has a non-compensated relationship as a Board member with International Headache Society that is relevant to �鶹��ýӳ�� interests or activities.
	No disclosure on file
Paul B. Hart	Mr. Hart has nothing to disclose.
Vincent H. Bargnes III	Mr. Bargnes has received research support from Harry Dent Family Foundation.

�鶹��ýӳ��

�鶹��ýӳ��